J Clin Med Kaz 2015; 3(37):14-18
Systemic administration of autologous mononuclear precultured bone marrow stem cells in heart failure
Authors: Aliya Dzholdasbekova, Galina Fedotovskikh, Manarbek Askarov, Bayan Komsabakova, Ainur Baigenzhina, Argul Kairatova, Gulden Abylkassymova
Number of views: 240
The Aim: Heart failure (HF) is the major cause of death worldwide. Despite the available pharmacotherapy, prognosis is usually harsh. Here we assessed the safety and efficacy of autologous bone marrow-derivedmononuclear cell (BMMC)retransplantation in HF (left ventricular ejection fraction, LVEF <45%) at one-year follow-up.
Methods: A whole number of 104 patients were included to the study (male=84 and female=20), age 27 untill 65 with Heart failure. All patients underwent standard examination (12-lead ECG, echocardiography, 6-minute walking test and laboratory tests).
Results: After systemic BMMC retransplantation, EF was shown to rise at 12 months for both DCMP and ISCM (32,1+/-1,3 vs 41,3+/-1,6% and 32,2+/-1,2% vs 39,3+2,6%, respectively; p-value<0,005). ProBNP recognized as an early marker of HF tend to reduce sufficiently by 3 monthsand continued to recover at one-year follow-up for both diseases (3266,+/-344,4 vs 361+/-35,9 ng/ml; p-value<0,0001 and 4618+/-267 vs 286+/-35,9 ng/ml; p-value<0,0001 for ICMP and DCMP, respectively).
Conclusion: Our results suggest BMMC transplantation is safe and well tolerated. BMMC infusion has improved systolic myocardial function, and a consequence has delayed the progression of HF, which is confirmed by recovering proBNP. Moreover, BMMC transplantation might favor by preliminarycell cultivation due to enhanced mitochondrial function.